Townsquare Capital LLC Acquires 9,075 Shares of Vericel Co. (NASDAQ:VCEL)

Townsquare Capital LLC lifted its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 17.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,936 shares of the biotechnology company's stock after acquiring an additional 9,075 shares during the period. Townsquare Capital LLC owned approximately 0.12% of Vericel worth $3,291,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after purchasing an additional 701,064 shares during the period. Raymond James Financial Inc. acquired a new stake in Vericel during the 4th quarter worth approximately $28,126,000. William Blair Investment Management LLC lifted its stake in Vericel by 66.3% in the fourth quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock valued at $69,100,000 after buying an additional 501,736 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Vericel by 25.4% in the fourth quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company's stock valued at $61,630,000 after buying an additional 227,675 shares during the period. Finally, Congress Asset Management Co. boosted its holdings in shares of Vericel by 12.6% in the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock valued at $79,847,000 after buying an additional 162,419 shares during the period.

Analyst Upgrades and Downgrades

VCEL has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Stephens restated an "overweight" rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Truist Financial reduced their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Finally, StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $60.86.

Vericel Price Performance

VCEL stock traded up $0.41 during mid-day trading on Friday, reaching $41.23. The company had a trading volume of 343,268 shares, compared to its average volume of 391,030. Vericel Co. has a 52 week low of $37.76 and a 52 week high of $63.00. The stock has a 50 day simple moving average of $47.42 and a two-hundred day simple moving average of $51.47. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 687.28 and a beta of 1.61.

Insiders Place Their Bets

In other Vericel news, insider Jonathan Siegal sold 3,908 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. This represents a 76.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the sale, the director now owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,942 shares of company stock valued at $2,724,548. 7.20% of the stock is currently owned by corporate insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.